Author:
Wang Xuan,Ji Qing,Yan Xieqiao,Lian Bin,Si Lu,Chi Zhihong,Sheng Xinan,Kong Yan,Mao Lili,Bai Xue,Tang Bixia,Li Siming,Zhou Li,Cui Chuanliang,Guo Jun
Reference21 articles.
1. The blockade of immune checkpoints in cancer immunotherapy.;Pardoll;Nat Rev Cancer.,2012
2. Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.;Brahmer;J Clin Oncol.,2010
3. PD-1 and PD-1 ligands: from discovery to clinical application.;Okazaki;Int Immunol.,2007
4. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer.;Topalian;N Engl J Med.,2012
5. Safety and tumor responses with Lambrolizumab (Anti–PD-1) in melanoma.;Hamid;N Engl J Med.,2013
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献